Payment overview · 2025
General Payments
$2,369.30
93 reported records · 27 companies
Healthcare provider profile · identity verified
Dennis Charles Carter, MD
Allopathic & Osteopathic Physicians|Family Medicine · MURFREESBORO, TN · NPI 1831287630
Verified facts
What the public records show
CMS Open Payments records show Dennis Charles Carter, MD received $2,369.30 in general payments during 2025 across 93 reported records.
Astellas Pharma US Inc accounted for 12.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 38 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Kerendia, Mounjaro, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Eliquis by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Lantus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $287.14 | 12.1% | 7 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $219.41 | 9.3% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $214.54 | 9.1% | 9 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $198.65 | 8.4% | 12 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $197.72 | 8.3% | 5 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $148.08 | 6.2% | 3 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $141.60 | 6.0% | 6 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $137.19 | 5.8% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $112.10 | 4.7% | 7 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $83.68 | 3.5% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $82.99 | 3.5% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $79.13 | 3.3% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $62.05 | 2.6% | 3 | 2025 |
| RGH Enterprises LLC | Unresolved — no canonical attribution shown | $48.20 | 2.0% | 1 | 2025 |
| Noven Therapeutics, LLC | Unresolved — no canonical attribution shown | $45.55 | 1.9% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $39.98 | 1.7% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $38.78 | 1.6% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $35.86 | 1.5% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $29.88 | 1.3% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $29.25 | 1.2% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $25.53 | 1.1% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.69 | 0.9% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $21.12 | 0.9% | 1 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $20.05 | 0.8% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $17.71 | 0.8% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $16.23 | 0.7% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.19 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,309.30 | 92 |
| Education | $60.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $227.14 | 6 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $219.41 | 5 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $197.72 | 5 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $148.08 | 3 | 2025 |
Source payment records
|
|||||
| ONPATTRO Normalized: onpattro |
Drug | Alnylam Pharmaceuticals Inc. | $141.60 | 6 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $118.79 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $101.80 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $98.60 | 6 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $96.85 | 8 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $83.68 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $79.13 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $76.81 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $72.59 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $63.92 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $62.05 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $50.82 | 3 | 2025 |
Source payment records
|
|||||
| Xelstrym Normalized: xelstrym |
Drug | Noven Therapeutics, LLC | $45.55 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $43.05 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $42.04 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $42.04 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $40.13 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $39.98 | 2 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $38.78 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $38.36 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $29.88 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $29.25 | 1 | 2025 |
Source payment records
|
|||||
| LAGEVRIO Normalized: lagevrio |
Drug | Merck Sharp & Dohme LLC | $25.53 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $25.32 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $25.32 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $25.32 | 1 | 2025 |
Source payment records
|
|||||
| KEVEYIS Normalized: keveyis |
Drug | Xeris Pharmaceuticals, Inc. | $21.69 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $21.12 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $21.12 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $20.87 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $20.05 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $17.71 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $16.23 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $15.19 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 68 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 84 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 62 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 54 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 30 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
84 | 17 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
62 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
62 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
54 | 18 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
30 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
68 | 14 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 453 | 138 |
| Atorvastatin Calcium | Atorvastatin Calcium | 445 | 121 |
| Losartan Potassium | Losartan Potassium | 396 | 103 |
| Levothyroxine Sodium | Levothyroxine Sodium | 341 | 90 |
| Lisinopril | Lisinopril | 326 | 101 |
| Gabapentin | Gabapentin | 313 | 63 |
| Pantoprazole Sodium | Pantoprazole Sodium | 305 | 71 |
| Meloxicam | Meloxicam | 297 | 68 |
| Omeprazole | Omeprazole | 286 | 78 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 239 | 71 |
| Furosemide | Furosemide | 238 | 61 |
| Metoprolol Succinate | Metoprolol Succinate | 218 | 61 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 213 | 43 |
| Metformin Hcl | Metformin Hcl | 204 | 61 |
| Potassium Chloride | Potassium Chloride | 197 | 48 |
| Hydrochlorothiazide | Hydrochlorothiazide | 193 | 56 |
| Carvedilol | Carvedilol | 184 | 48 |
| Allopurinol | Allopurinol | 180 | 46 |
| Simvastatin | Simvastatin | 175 | 49 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 164 | 41 |
| Tamsulosin Hcl | Tamsulosin Hcl | 159 | 43 |
| Glimepiride | Glimepiride | 153 | 40 |
| Alprazolam | Alprazolam | 151 | 31 |
| Pioglitazone Hcl | Pioglitazone Hcl | 141 | 41 |
| Trazodone Hcl | Trazodone Hcl | 131 | 30 |
| Clopidogrel | Clopidogrel Bisulfate | 130 | 37 |
| Metformin Hcl Er | Metformin Hcl | 130 | 37 |
| Pravastatin Sodium | Pravastatin Sodium | 124 | 37 |
| Nifedipine Er | Nifedipine | 117 | 33 |
| Fluticasone Propionate | Fluticasone Propionate | 114 | 42 |
| Spironolactone | Spironolactone | 114 | 35 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 109 | 21 |
| Sertraline Hcl | Sertraline Hcl | 103 | 25 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 98 | 25 |
| Farxiga | Dapagliflozin Propanediol | 84 | 17 |
| Finasteride | Finasteride | 84 | 22 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 80 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 79 | 21 |
| Montelukast Sodium | Montelukast Sodium | 77 | 26 |
| Famotidine | Famotidine | 76 | 17 |
| Lovastatin | Lovastatin | 76 | 23 |
| Tramadol Hcl | Tramadol Hcl | 74 | 17 |
| Prednisone | Prednisone | 72 | 35 |
| Hydralazine Hcl | Hydralazine Hcl | 70 | 18 |
| Xarelto | Rivaroxaban | 69 | 15 |
| Eliquis | Apixaban | 68 | 14 |
| Januvia | Sitagliptin Phosphate | 66 | 12 |
| Lorazepam | Lorazepam | 63 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 63 | 22 |
| Atenolol | Atenolol | 62 | 18 |
| Buspirone Hcl | Buspirone Hcl | 62 | 17 |
| Jardiance | Empagliflozin | 62 | 17 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 62 | 22 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 62 | 21 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 61 | 20 |
| Ibuprofen | Ibuprofen | 59 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 59 | 17 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 58 | 14 |
| Clonidine Hcl | Clonidine Hcl | 57 | 19 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 57 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 56 | 16 |
| Ozempic | Semaglutide | 54 | 18 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 53 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 51 | 20 |
| Celecoxib | Celecoxib | 50 | suppressed |
| Bupropion Xl | Bupropion Hcl | 49 | 12 |
| Promethazine Hcl | Promethazine Hcl | 48 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 47 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 47 | 14 |
| Warfarin Sodium | Warfarin Sodium | 47 | 11 |
| Acarbose | Acarbose | 46 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 45 | 16 |
| Diazepam | Diazepam | 43 | suppressed |
| Estradiol | Estradiol | 43 | 11 |
| Ezetimibe | Ezetimibe | 43 | 16 |
| Meclizine Hcl | Meclizine Hcl | 43 | 20 |
| Breo Ellipta | Fluticasone/Vilanterol | 41 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 41 | suppressed |
| Levetiracetam | Levetiracetam | 40 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 39 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 38 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 38 | suppressed |
| Clonazepam | Clonazepam | 36 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 36 | 14 |
| Fluconazole | Fluconazole | 36 | 14 |
| Pregabalin | Pregabalin | 34 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 34 | suppressed |
| Verapamil Er | Verapamil Hcl | 34 | suppressed |
| Cilostazol | Cilostazol | 33 | suppressed |
| Levemir Flexpen | Insulin Detemir | 33 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 31 | 12 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Rybelsus | Semaglutide | 30 | 12 |
| Tradjenta | Linagliptin | 30 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 29 | suppressed |
| Cephalexin | Cephalexin | 29 | 26 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 28 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 28 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 28 | suppressed |
| Temazepam | Temazepam | 28 | suppressed |
| Trulicity | Dulaglutide | 28 | suppressed |
| Azithromycin | Azithromycin | 27 | 27 |
| Bumetanide | Bumetanide | 27 | 13 |
| Doxazosin Mesylate | Doxazosin Mesylate | 27 | suppressed |
| Ketoconazole | Ketoconazole | 27 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 27 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 27 | suppressed |
| Guanfacine Hcl | Guanfacine Hcl | 26 | suppressed |
| Mirtazapine | Mirtazapine | 26 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 25 | 11 |
| Risperidone | Risperidone | 25 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Ramipril | Ramipril | 24 | suppressed |
| Baclofen | Baclofen | 22 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 22 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 22 | suppressed |
| Indapamide | Indapamide | 22 | suppressed |
| Nystatin | Nystatin | 22 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 21 | suppressed |
| Cimetidine | Cimetidine | 21 | suppressed |
| Mupirocin | Mupirocin | 21 | suppressed |
| Naproxen | Naproxen | 21 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 20 | suppressed |
| Colchicine | Colchicine | 20 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | suppressed |
| Gemfibrozil | Gemfibrozil | 20 | suppressed |
| Glipizide | Glipizide | 20 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 20 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 20 | suppressed |
| Fenofibrate | Fenofibrate | 19 | suppressed |
| Lactulose | Lactulose | 19 | suppressed |
| Methocarbamol | Methocarbamol | 19 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 16 |
| Metoclopramide Hcl | Metoclopramide Hcl | 18 | suppressed |
| Mounjaro | Tirzepatide | 18 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 18 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Eszopiclone | Eszopiclone | 17 | suppressed |
| Memantine Hcl | Memantine Hcl | 17 | suppressed |
| Premarin | Estrogens, Conjugated | 17 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Telmisartan | Telmisartan | 17 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 16 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Linzess | Linaclotide | 15 | suppressed |
| Metolazone | Metolazone | 15 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 15 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Kerendia | Finerenone | 14 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Victoza 3-Pak | Liraglutide | 14 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 12 |
| Diltiazem 24hr Er | Diltiazem Hcl | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Methylprednisolone | Methylprednisolone | 12 | 12 |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 12 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Methotrexate | Methotrexate Sodium | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,369.30 · 93 records | Astellas Pharma US Inc | ABRYSVO, ACCRUFER, AIRSUPRA, Auvelity, BREZTRI, CAPLYTA, COMIRNATY, Cologuard Collection Kit, ELIQUIS, FARXIGA, Fluad, Flucelvax, GEMTESA, INSPIRE, JARDIANCE, KEVEYIS, Kerendia, LAGEVRIO, MOUNJARO, NURTEC ODT, ONPATTRO, Ozempic, PREVNAR 20, QULIPTA, REPATHA, REXULTI, Rybelsus, TZIELD, UBRELVY, VOQUEZNA, VRAYLAR, VYEPTI, Veozah, XIFAXAN, XYOSTED, Xelstrym, ZAVZPRET, ZEPBOUND | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error